How the Medical Industry Could Produce the Biggest AI Stock Winners

InvestorPlace05-07

Meet Luke Lango Key Takeaways: Between early November 2023 and late February 2024, the SPDR S&P Biotech ETF soared more than 55%. And certain biotech stocks have soared much more. Year-to-date,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2433286810?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-05-07 02:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2433286810","market":"us","top_or_hot":-1,"title":"How the Medical Industry Could Produce the Biggest AI Stock Winners","media":"InvestorPlace","content":"<div>\n<p>Meet Luke Lango\t\t\n\n\n\n\nKey Takeaways:\n\nBetween early November 2023 and late February 2024, the SPDR S&P Biotech ETF soared more than 55%. And certain biotech stocks have soared much more. Year-to-date,...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2024/05/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/\">Source Link</a>\n\n</div>\n","source":"investorplace_stock_picks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How the Medical Industry Could Produce the Biggest AI Stock Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow the Medical Industry Could Produce the Biggest AI Stock Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-07 02:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/hypergrowthinvesting/2024/05/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Meet Luke Lango\t\t\n\n\n\n\nKey Takeaways:\n\nBetween early November 2023 and late February 2024, the SPDR S&P Biotech ETF soared more than 55%. And certain biotech stocks have soared much more. Year-to-date,...</p>\n\n<a href=\"https://investorplace.com/hypergrowthinvesting/2024/05/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SKYE","symbol_name":"Skye Bioscience Inc.","start_time":0,"source_url":"https://investorplace.com/hypergrowthinvesting/2024/05/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/","article_id":"2433286810","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2433286810","pubTimestamp":1715018766,"sourceInfo":{"source_id":"investorplace_stock_picks","name":"InvestorPlace stock picks"},"weMediaInfo":null,"summary":"The application of AI in biology holds the potential to unlock enormous economic value for one simple reason – data.","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"SKYE":"Skye Bioscience Inc.","IE00BJTD4N35.SGD":"Neuberger Berman US Long Short Equity A1  Acc SGD-H","BK4127":"投资银行业与经纪业","TAK":"武田制药","IE00B7KXQ091.USD":"Janus Henderson Balanced A Inc USD","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4516":"特朗普概念","IE00B775SV38.USD":"NEUBERGER BERMAN US MULTICAP OPPORTUNITIES \"A\" (USD) ACC","BK4539":"次新股","AZN":"阿斯利康","BK4554":"元宇宙及AR概念","IE00B3S45H60.SGD":"Neuberger Berman US Multicap Opportunities A Acc SGD-H","LU0109391861.USD":"富兰克林美国机遇基金A Acc","BK4532":"文艺复兴科技持仓","IE00B19Z9505.USD":"美盛-美国大盘成长股A Acc","JNJ":"强生","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","IE00BJJMRX11.SGD":"Janus Henderson Balanced A Acc SGD","ELEV":"Elevation Oncology, Inc.","SNY":"赛诺菲安万特","LU0098860793.USD":"FRANKLIN INCOME \"A\" INC","LU0079474960.USD":"联博美国增长基金A","LU0127658192.USD":"EASTSPRING INVESTMENTS GLOBAL TECHNOLOGY \"A\" (USD) ACC","BK4534":"瑞士信贷持仓","MSFT":"微软","CRBP":"Corbus Pharmaceuticals Holdings, Inc.","IE00B1XK9C88.USD":"PINEBRIDGE US LARGE CAP RESEARCH ENHANCED \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","NVDA":"英伟达","BK4007":"制药","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","LU0061474960.USD":"天利环球焦点基金AU Acc","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4535":"淡马锡持仓","XBI":"SPDR S&P Biotech ETF","BK4559":"巴菲特持仓","BK4538":"云计算","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","BK4550":"红杉资本持仓","IE0004445015.USD":"JANUS HENDERSON BALANCED \"A2\" (USD) ACC","BK4551":"寇图资本持仓","LU0882574055.USD":"富达全球健康医疗A ACC","BK4097":"系统软件","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","IE00BFSS8Q28.SGD":"Janus Henderson Balanced A Inc SGD-H","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","BK4549":"软银资本持仓","BK4548":"巴美列捷福持仓"},"translate_title":"医疗行业如何产生最大的人工智能股票赢家","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1,"CRBP":1,"ELEV":1,"JNJ":1,"MSFT":1,"NVDA":1,"SKYE":1,"SNY":1,"TAK":1,"XBI":1},"content_text":"Meet Luke Lango\t\t\n\n\n\n\nKey Takeaways:\n\nBetween early November 2023 and late February 2024, the SPDR S&P Biotech ETF soared more than 55%. And certain biotech stocks have soared much more. Year-to-date, Elevation Oncology is up more than 600%. Skye Bioscience is up nearly 380%, and Corbus Pharmaceuticals is up more than 525%.\nThe drug discovery and development process is prohibitively long and expensive. But AI can significantly shorten and cheapen it.\nMorgan Stanley believes that AI-powered drug discovery will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!\n\n\n\n\n\n \n\n\nEditor’s note: “How the Medical Industry Could Produce the Biggest AI Stock Winners” was previously published in April 2024. It has since been updated to include the most relevant information available.\nA bulk of the AI-related headlines that dominate the mainstream media have been centered around software developers and their AI assistants, like OpenAI’s ChatGPT and Microsoft’s (MSFT) Copilot. But the biggest AI stock boom is happening in an entirely different sector. And for the most part, it’s gone largely unnoticed.\nWe’re talking about biotech stocks.\nBetween early November 2023 and late February 2024, the SPDR S&P Biotech ETF (XBI) soared more than 55%. And certain biotech stocks rocketed much more.\nYear-to-date, Elevation Oncology (ELEV) is up more than 600%. Skye Bioscience (SKYE) is up nearly 380%, and Corbus Pharmaceuticals (CRBP) is up more than 525%.\nWhy the huge breakout in biotech?\nIn part, it’s thanks to AI. And considering that this powerful emerging technology is still in its infancy, we think there’s a ton of room for these stocks to run.\nIt’s All About the Data\nAI’s application in biology holds the potential to unlock enormous economic value for one simple reason: data.\nThe more data, the better the AI.\nAnd when it comes to the human body, there is no dearth of quality data. In fact, there is more high-quality data than anywhere else on Earth.\nThat’s because, like computers, humans are really nothing more than a bunch of data strung together.\nAt their core, computers are just a bunch of 1s and 0s coded in sequence, with each number corresponding to a certain action for the computer to perform. Humans, similarly, are a bunch of As, Gs, Cs, and Ts strung together – or the four base types found in human DNA molecules – with each determining a person’s characteristics, traits, and even actions.\nHumans are full of data.\nApply AI to all that data, and you will change the world.\nRevolutionizing Medicine With AI\nThe human body has proven to be quite a complex thing. There’s certainly no scarcity of illness or disease that impact folks around the world. And while humanity has made great strides in discovering treatments and cures, countless afflictions remain a reality. \nBut AI has the potential to solve the myriad problems that plague all humans.\nConsider this: It takes about $900 million and 13.5 years to develop a new successful drug.\nThe drug development process is so expensive and time-consuming that firms cannot afford to push that many drugs forward. This creates a huge shortage in drug candidates and programs relative to what is possible given all the permutations of human biological data.\nBut AI can significantly shorten and cheapen this process.\nWhy does it take so long to find new drugs? Because the universe of biological data is enormous. It takes scientists great effort to sort through all the data, uncover the root causes of diseases, and formulate compounds to fight those diseases.\nBut AI can automate that entire process. It can map out genetic data, identify mutations, and run simulations to find the right compounds and combat those mutations –  all almost instantly. \nEssentially, researchers can use AI to find new drug candidates much faster than is currently possible.\nAnd this is already happening.  \nLast year, Japanese pharma giant Takeda Pharmaceutical (TAK) bought an experimental psoriasis drug for $4 billion – a drug that was created in only six months by using AI.\nIt isn’t alone.\nOther pharma giants like Bayer, Roche, Sanofi (SNY) and AstraZeneca (AZN) are actively using AI technology for drug discovery purposes.\nThe future of AI-powered drug discovery starts now.\nThis is big business.\nThe Final Word\nResearch firm Deep Pharma Intelligence estimates that investments in the field of AI-powered drug discovery have tripled over the past four years to nearly $25 billion. \nMorgan Stanley believes this tech will lead to an additional 50 novel therapies being brought to market over the next decade, with annual sales in excess of $50 billion!\nIn other words, a $50 billion AI drug discovery revolution starts now.\nAnd, of course, AI’s applications in healthcare aren’t limited to discovering viable drug candidates.\nIn fact, back in March, Nvidia (NVDA) held its GPU Technology Conference (GTC), an event for AI developers and enthusiasts. And the tech titan revealed that it’s partnering with Johnson & Johnson (JNJ). The two will develop AI to help doctors perform surgery.\nThis is a huge development. After all, according to Nvidia, “J&J MedTech is in 80% of the world’s operating rooms and trains more than 140,000 healthcare professionals each year.” It’s very likely that within the next decade, almost all surgeries will be at least partially automated by AI.\nThe potential that artificial intelligence holds for the healthcare industry is enormous. And as such, it’s high time to bulk up your portfolio with top-of-the-line AI stocks.\nDiscover which high-octane stocks we’re piling into.\nOn the date of publication, Luke Lango did not have (either directly or indirectly) any positions in the securities mentioned in this article.\nP.S. You can stay up to speed with Luke’s latest market analysis by reading our Daily Notes! Check out the latest issue on your Innovation Investor or Early Stage Investor subscriber site.\nTechnology, Artificial IntelligenceGrowth Stocks \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSubmit\n\n\n\n\n\n\n\n Luke Lango\nEditor, Hypergrowth Investing\n\n\nMeet Luke Lango\nBy uncovering early investments in hypergrowth industries, Luke Lango puts you on the ground-floor of world-changing megatrends.\n\n\n\n\n\t\t\t\tLearn more about Luke\t\t\t\n\n\n\n\n\nArticle printed from InvestorPlace Media, https://investorplace.com/hypergrowthinvesting/2024/05/how-the-medical-industry-could-produce-the-biggest-ai-stock-winners/.\n©2024 InvestorPlace Media, LLC","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2433286810"}